Eureka Therapeutics Competitors and Similar CompaniesClear all
Eureka Therapeutics's competitors and similar companies include Immatics, MABION and Oncologie.
 Eureka Therapeutics Eureka Therapeutics is a biotechnology company focused on discovery of novel antibody immunotherapies for the treatment of cancer.
|  Immatics Immatics is a biotechnology company that is primarily engaged in the research and development of T cell redirecting immunotherapies for the treatment of cancer. |  MABION Mabion is a biotechnology company engaged in research and development of biotechnology and biosimilar drugs to treat cancer, autoimmune, and metabolic diseases. | ||
Founding Date | Founding Date 2006 | Founding Date N/A | Founding Date 2007 | Founding Date 2018 |
Type | Type Private | Type Public | Type Public | Type Private |
Tags | ||||
Locations | Locations Emeryville, US HQ | Locations Tübingen, DE HQ Frankfurt Am Main, DE München, DE Houston, US | Locations Konstantynów Łódzki, PL HQ | Locations Waltham, US HQ Shanghai, CN Boston, US |
Employees | Employees 432% decrease | Employees 29723% increase | Employees 95 | Employees 8 |
Valuation ($) | Valuation ($) N/A | Valuation ($) 1.1 b | Valuation ($) 21.7 m | Valuation ($) N/A |
Financial | ||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) €48.3m (FY, 2025) | Revenue (est.) zł15.8m (FY, 2025) | Revenue (est.) N/A |
Cost of goods | Cost of goods N/A | Cost of goods N/A | Cost of goods zł24.1m (FY, 2025) | Cost of goods N/A |
Gross profit | Gross profit N/A | Gross profit €53m (FY, 2025) | Gross profit (zł7.2m) (FY, 2025) | Gross profit N/A |
Net income | Net income N/A | Net income (€196.4m) (FY, 2025) | Net income (zł62.6m) (FY, 2025) | Net income N/A |
Funding | ||||
Latest funding round | Latest funding round $ 45m (over 6 years ago) | Latest funding round N/A | Latest funding round N/A | Latest funding round $ 80m (about 7 years ago) |
Total funding raised | Total funding raised $ 130.4m | Total funding raised $ 267.3m | Total funding raised N/A | Total funding raised $ 96.5m |
For sources of this data, please see the company profile
View Company Profiles
Immatics
HQ
Tübingen, DE
Employees
297↑ 23% increase
Immatics is a biotechnology company that is primarily engaged in the research and development of T cell redirecting immunotherapies for the treatment of cancer.
View companyMABION
HQ
Konstantynów Łódzki, PL
Employees
95
Mabion is a biotechnology company engaged in research and development of biotechnology and biosimilar drugs to treat cancer, autoimmune, and metabolic diseases.
View company